TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Genetic-specific Effects of Fructose on Liver Lipogenesis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects 12 - 40 years~2. No history of alcohol abuse (\> 7 drinks per week)~3. History of fructose intake of \< 14 drinks per week~4. Caucasian ethnicity~5. BMI \> 25kg/m² - 32kg/m² or 85th -99th percentile but otherwise healthy~Exclusion Criteria:~1. ages \< 12 and \> 40 years~2. Pregnant/lactating~3. known alcohol abuse or fructose intake \> 14 drinks per week~4. not of Caucasian ethnicity~5. glucose levels \> 100 mg/dL if fasting, \> 140mg/dL if within 2 hours post meal and \> 200 mg/dL if random sample~6. taking anti-hypertensive, anti-diabetic, uric acid and/or lipid-lowering medications~7. known diagnosis of diabetes, fructose intolerance, chronic kidney disease, NAFLD or any liver-related disease, hypertriglyceridemia, polycystic ovary syndrome, hypothyroidism, obstructive sleep apnea, hypopituitarism and hypogonadism~8. BMI \< 25kg/m² or \> 32 kg/m² or \< 85th or \> 99th percentile~9. Liver fat fraction \>5% as per baseline MRI scan

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- High GRS group (Type: EXPERIMENTAL): This group consists of individuals who are in the highest quartile of the genetic risk score (GRS) and will ingest one sugar drink (equal to 2 soft drinks) per day for 3 weeks. The GRS is computed by adding the number of alleles that increase the risk for liver lipogenesis or fatty liver.
- Low GRS group (Type: EXPERIMENTAL): This groups consists of individuals who are in the lowest quartile of the genetic risk score (GRS) and will ingest one sugar drink (equal to 2 soft drinks) per day for 3 weeks. The GRS is computed by adding the number of alleles that increase the risk for liver lipogenesis or fatty liver.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tulobuterol Patch in Pediatric Patients Undergoing Tonsillectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* pediatric patients undergoing tonsillectomy~Exclusion Criteria:~* recent upper respiratory infection (2weeks)~* Allergy to tulobuterol patch~* Patients receiving catecholamine (epinephrine, isoproterenol)~* hyperthyroidism~* hypertension~* cardiac disease~* Diabetes melitus~* atopic dermatitis~* Asthma

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Tulobuterol patch (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of B-cell chronic lymphocytic leukemia (CLL) requiring therapy and meeting the following criteria:~  * Previously untreated disease~ * Peripheral blood morphology, excluding other leukemia and low-grade lymphoma in leukemic phase~ * Cell markers: CD5+, CD23+, SmIg (weak), CD79b-, FMC7-~ * Persistent lymphocytosis (greater than 10,000/mm\^3)~ * At least 40% bone marrow infiltration~* Stage 0 or I progressive disease indicated by at least one of the following:~  * Persistent rise in lymphocyte count with doubling time less than 12 months~ * Downward trend in hemoglobin and/or platelet count~ * At least 50% increase in size of liver and/or spleen and/or lymph nodes~ * Appearance of lymphadenopathy, hepatomegaly, or splenomegaly~ * Constitutional symptoms caused by disease~    * Pyrexia~   * Night sweats~   * Weight loss OR~* Stage II or III~PATIENT CHARACTERISTICS:~Age:~* Not specified~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* See Disease Characteristics~Hepatic:~* Bilirubin no greater than 2 times upper limit of normal (ULN)\*~* SGOT/SGPT no greater than 2 times ULN\* NOTE: \* Unless due to CLL~Renal:~* Creatinine clearance at least 30 mL/min~Other:~* No other cancer or life-threatening disease~* Not pregnant~* Fertile patients must use effective contraception during and for 6 months after study therapy~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* No concurrent corticosteroids (e.g., dexamethasone) as antiemetics~Radiotherapy~* Not specified~Surgery~* Not specified

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RESTART C0168Z05 Rheumatoid Arthritis Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have rheumatoid arthritis~* Patients must have greater than or equal to 6 tender joints and greater than or equal to 6 swollen joints~* Patients must have inadequate disease response to etanercept or adalimumab~* Patients must have received etanercept or adalimumab in combination with methotrexate for a minimum of at least 3 months prior to the screening visit. The last dose of etanercept must have been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion.~Exclusion Criteria:~* Patients who have a history of latent or active TB~* Have inflammatory disease other than rheumatoid arthritis~* Have had a chronic or recurrent infectious disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: OTHER): Infliximab3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preemptive Local Anesthesia in Vaginal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women undergoing vaginal hysterectomy with McCall's culdoplasty

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PLA (Type: EXPERIMENTAL): Active preemptive local analgesia.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for preemptive local analgesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of non-operable or metastatic non-functioning, well differentiated advanced GI NET, confirmed by cytology or histology. In case of liver metastasis, neuroendocrine tumours of unknown origin are accepted.~* Confirmation of diagnosis of neuroendocrine carcinoma of low to intermediate histology grade~* Radiologically documented disease progression within 12 months prior to inclusion in the study. If the patient received anticancer treatment within the past 12 months, disease progression must be documented by radiology during or after taking this medication~* Adequate bone marrow. liver and renal function~Exclusion Criteria:~* Previous treatment with mTOR inhibitors (sirolimus, temsirolimus, everolimus, deforolimus).~* Patients with any serious disease and/or an uncontrolled clinical condition~* Patients on chronic treatment with corticosteroids or any other immunosuppressive agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus + Octreotide LAR treatment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* a gestational age of 23 0/7-27 6/7 weeks,~* a postnatal age \< 12 hours~* the necessity for any form of positive pressure support (mechanical or nasal ventilation or CPAP~Exclusion Criteria:~* involve a clinical decision not to administer therapies (infant not considered viable)~* dysmorphic features or congenital malformations that adversely affect life expectancy or neurodevelopment and known or suspected congenital heart disease

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Hours
- Healthy Volunteers: f

Study Arms:
- inhaled Budesonide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Autologous Cultured Adipose -Derived Stem Cells for the Crohn's Fistula

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Older than 18 years~* Prior diagnosis of Crohn's disease~* patients who have Crohn's fistula~* negative for serum beta-HCG for woman of childbearing age~* agreement to participate, with signed informed-consent~Exclusion Criteria:~* patients who have allergy to bovine-derived materials or an anesthetic~* patients with a diagnosis of auto immune disease except for Crohn's disease~* Diagnosis of HBV, HCV, HIV and other infectious disease~* Patients who have a symptom of septicemia~* Patients with a diagnosis of active Tuberculosis~* Patient who are pregnant or breast-feeding~* Patients who are unwilling to use an effective method of contraception during the study~* Patients with a diagnosis of Inflammatory Bowel Disease except for Crohn's disease~* Patients who are sensitive to Fibrin glue~* Patients who have a clinically relevant history of abuse of alcohol or drugs, habitual smoker~* Insufficient adipose tissue for manufacturing of ADIPOPLUS~* Patients who are considered not suitable for the study by investigator~* Patients with a diagnosis of active refractory Crohn's disease~* Patients who have history of surgery for malignant cancer in the past 5 years~* Patients who have \> 2 cm diameter of fistula

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ADIPOPLUS (Type: EXPERIMENTAL): patients with a fistula in Crohn's disease

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has completed a colonoscopy according to the American Gastroenterological Association criteria with no clinically significant findings~* Patient has successfully completed protocol procedures (with no clinically significant findings)~* Patient meets protocol criteria for Chronic Constipation(CC): \< 3 bowel movements per week and reports one or more of the following symptoms for at least 12 weeks:~  1. Straining during more than 25% of BMs~ 2. Lumpy or hard stools during more than 25% of BMs~ 3. Sensation of incomplete evacuation during more than 25% of BMs~* Patient demonstrates continued chronic constipation and bloating through Pretreatment Period~* Patient is compliant with Interactive voice response System (IVRS)~Exclusion Criteria:~* Patient has a history of loose or watery stools~* Patient has symptoms of or been diagnosed with Irritable Bowel Syndrome (IBS)~* Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility~* Patient has any protocol-excluded or clinically significant medical or surgical history that would limit the patient's ability to complete or participate in this clinical trial or could confound the study assessments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Linaclotide 290 micrograms (Type: EXPERIMENTAL): Linaclotide 290 micrograms
- Linaclotide 145 Micrograms (Type: EXPERIMENTAL): Linaclotide 145 micrograms
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tanezumab in Osteoarthritis of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Osteoarthritis of the knee according to ACR criteria with a Kellgren-Lawrence x-ray grade of 2.~* Unwilling or unable to take non-opiate pain medications, for whom non-opiate pain medications have not provided adequate pain relief or are candidates for knee injections arthroplasty or replace surgery.~* Pain level and function levels as required by the protocol at Screening and Baseline.~* Willing to discontinue pain medications (acetaminophen will be permitted up to a certain level) before and during the study.~* Must agree to the contraceptive requirements of the protocol if applicable.~* Must agree to the treatment plan, scheduled visits, and procedures of the protocol.~Exclusion Criteria:~* Pregnancy or intent to become pregnant during the study~* BMI greater than 39~* other severe pain, significant cardiac, neurological or psychological conditions, or above the protocol limits for laboratory and blood pressure results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Tanezumab 10 mg (Type: EXPERIMENTAL): None
- Tanezumab 5 mg (Type: EXPERIMENTAL): None
- Tanezumab 2.5 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of TTR amyloidosis~* Adequate blood counts, liver and renal function~* Women of child-bearing potential must have a negative pregnancy test, cannot be breast feeding, and must use an adequate method of birth control~* Males agree to use appropriate contraception~* Willing and able to comply with protocol-required visit schedule and visit requirements and provide written informed consent.~Exclusion Criteria:~* Known human immunodeficiency virus (HIV) positive status~* Receiving antibiotics for bacterial infection within 7 days of screening~* Known or suspected systemic viral, parasitic or fungal infection~* Receiving an investigational agent within 30 days prior to study drug administration~* Poor cardiac function~* Considered unfit for the study by the Principal Investigator~* Known sensitivity to oligonucleotides~* Employee or family member of the sponsor or the clinical study site personnel.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ALN-TTR01 (Type: ACTIVE_COMPARATOR): None
- Sterile Normal Saline (0.9% NaCl) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits) should be enrolled in the study.~* A Filipino male or female aged at least 6 weeks at the time of the first vaccination.~* Written informed consent obtained from the parent or guardian of the subject.~Exclusion Criteria:~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* Any history of chronic gastrointestinal disease including any uncorrected congenital malformation of the GI tract.~* Any contraindications as stated in the Prescribing Information.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 24 Weeks
- Healthy Volunteers: t

Study Arms:
- Cohort Group (Type: None): Subjects received two oral doses of the Rotarix vaccine at the age of 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post-Embolic Rhythm Detection With Implantable Versus External Monitoring

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of the index event\* made by a stroke specialist of an acute ischemic stroke or TIA occurring within the previous 90 days. The event must be either:~  1. an arterial ischemic stroke confirmed by neuroimaging; or~ 2. transient ischemic attack with diffusion weighted positive lesion on MRI~* At least one 12-lead ECG has already been obtained as part of the routine clinical post-stroke/TIA work-up, and no ECGs have shown any episodes of atrial fibrillation or atrial flutter~* The patient is being actively investigated for the etiology of the stroke/TIA event and additional cardiac monitoring is desired to screen further for the possibility of occult paroxysmal atrial fibrillation/flutter~* Age 18 years or older~* Informed consent from the patient~* The patient is expected to survive at least 6 months.~Exclusion Criteria:~* Any previously documented atrial fibrillation or atrial flutter, i.e. a past history of atrial fibrillation/flutter or atrial fibrillation/flutter detected on ECG, Holter, or telemetry following the index stroke/TIA event (a remote history of transient perioperative atrial fibrillation is not exclusionary)~* Planned carotid endarterectomy or carotid artery stenting within 90 days~* Any condition for which there is already an indication for long term anticoagulation Pacemaker or implantable cardioverter defibrillator device~* Work-up for stroke that has already included extended (\>48 hour) external ECG (excluding telemetry)~* Stroke and/or comorbid illness will prevent completion of planned follow-up assessments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Implanted Loop Recorder (Type: EXPERIMENTAL): long-term implantable ECG (Medtronic Reveal LINQ) coupled with remote monitoring (MyCareLink) for 12 months
- External Loop Recorder (Type: EXPERIMENTAL): external event-triggered ECG loop recorder (Sorin Spiderflash-t) for 30 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects between 18 and 80 years of age;~* Scheduled to undergo primary unilateral first metatarsal bunionectomy;~* Anesthesiological and surgical procedures performed according to protocol;~* Moderate or severe baseline pain following bunionectomy on a VRS within 9 hours of termination of the continuous popliteal sciatic block or systemic analgesia;~* Pain following bunionectomy of at least 4 on an 11-point NRS within 9 hours of termination of the continuous popliteal sciatic block or systemic analgesia; American Society of Anesthesiologists (ASA) classification I-III.~Exclusion Criteria:~* History of seizure disorder;~* History of alcohol, medication or drug dependency, unstable psychological personality requiring intermittent or permanent treatment; severely impaired renal function, moderately or severely impaired hepatic function;~* Contraindications to, or history of allergy or hypersensitivity to CG5503, oxycodone, morphine, fentanyl hydrocodone, acetaminophen, heparin, or any compound planned to be used during the anesthesia, or their excipients;~* Pre-operative use within 12h prior to surgery or peri-operative use of non- steroidal anti-inflammatory drugs (NSAIDs);~* Treated regularly with opioid analgesic or NSAIDs within 30 days prior to screening;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): CG5503 IR 75mg 4 to 6 hourly for 72 hours
- 2 (Type: ACTIVE_COMPARATOR): Morphine IR 30 mg 4 to 6 hourly for 72 hours
- 3 (Type: PLACEBO_COMPARATOR): Matching placebo 4 to 6 hourly for 72 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete